Humacyte Faces Class Action Lawsuit Over FDA Compliance Issues and Stock Decline

Humacyte Faces Class Action Lawsuit Amid FDA Compliance Issues

Humacyte, Inc., a company focused on regenerative medicine and tissue engineering, is embroiled in a class action lawsuit initiated by Glancy Prongay & Murray LLP in the United States District Court for the Middle District of North Carolina. The lawsuit, registered under case number 1:24-cv-00954, represents individuals and entities that acquired Humacyte securities between May 10, 2024, and October 17, 2024. The legal action alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, stemming from claims that the company made materially false statements regarding its compliance with manufacturing practices, particularly concerning its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV).

The lawsuit follows a turbulent period for Humacyte, particularly marked by the FDA's requirement for additional time to review its BLA, which was announced on August 9, 2024. This disclosure revealed that compliance issues surfaced during inspections at Humacyte's Durham facility, leading to a significant 16.4% drop in the company's stock price. The situation escalated on October 17, 2024, when the FDA issued a Form 483 citing multiple violations, including inadequate quality oversight and insufficient microbial testing protocols, which resulted in another 16.35% decrease in stock value. These reports have raised concerns about the company's operational integrity and its ability to secure FDA approval for the ATEV, a product that could have substantial implications for patients requiring vascular grafting solutions.

The allegations within the lawsuit assert that Humacyte's management failed to disclose critical information regarding the risks associated with the FDA's review process and the compliance issues affecting its manufacturing practices. This lack of transparency is believed to have misled investors about the potential for regulatory approval of the ATEV, ultimately jeopardizing the company's market position. Investors affected by these developments have a 60-day window to apply for lead plaintiff status, with GPM encouraging those who suffered financial losses to reach out for assistance in exploring their rights under federal securities laws.

In light of these developments, Humacyte's future remains uncertain as it navigates both legal challenges and regulatory scrutiny. The company’s ability to address the compliance issues raised by the FDA will be critical not only for its product approval prospects but also for restoring investor confidence. Meanwhile, investors are advised to remain vigilant about the implications of the lawsuit and its potential impact on the company’s operations and strategic direction.